Individualized Homeopathic Medicines in Stage I Essential Hypertension: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial

J Altern Complement Med. 2021 Jun;27(6):515-521. doi: 10.1089/acm.2020.0222. Epub 2021 Mar 23.


Objective: The present study assessed the feasibility of a definitive placebo-controlled trial for evaluating individualized homeopathy (IH) in stage I hypertension (HTN). Design: Double-blind, randomized (IH: 34, placebo: 34), placebo-controlled, parallel arms, pilot trial. Settings/Location: National Institute of Homoeopathy, India. Subjects: Patients suffering from stage I HTN. Interventions: IH and identical-looking placebo. Outcome measures: Feasibility issues, blood pressure (BP) and Measure Yourself Medical Outcome Profile-2 (MYMOP-2) were assessed for 6 months. Results: The recruitment and retention rates were 44.4% and 85.3%, respectively. Group differences were seemingly higher in the IH group than in the placebo group. Conclusions: Despite challenges in recruitment, an adequately powered efficacy trial appears feasible in the future.

Keywords: essential hypertension; homeopathy; pilot trial; placebo; randomized controlled trial.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Double-Blind Method
  • Essential Hypertension / drug therapy*
  • Humans
  • India
  • Materia Medica / therapeutic use*
  • Pilot Projects
  • Placebos


  • Materia Medica
  • Placebos